Psyence Biomedical Ltd.

As of March 31, 2026, Psyence Biomedical Ltd. carries a market capitalization of 5.64M, placing it among publicly traded companies globally. Its enterprise value stands at -1.80M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Psyence Biomedical Ltd. has 2.29M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Psyence Biomedical Ltd. maintains a current ratio of 14.62, meaning it holds 14.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2026, Psyence Biomedical Ltd. posted a negative return on equity (ROE) of -58.62, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -55.75, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 12.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Psyence Biomedical Ltd.'s stock has declined approximately 79.72% over the past 52 weeks. The 50-day moving average sits at 4.86, while the 200-day moving average is 4.03.

Over the twelve months ended March 31, 2026, Psyence Biomedical Ltd. generated - - in revenue and converted that into -6.94M in net income, yielding earnings per share of -12.56. EBITDA reached -7.44M, while operating income came in at -5.95M.

These figures are as of March 31, 2026. Total book value stands at 16.94M, with working capital of 8.49M providing operational flexibility.

Psyence Biomedical Ltd. produced -8.14M in operating cash flow over the twelve months ended March 31, 2026. After subtracting -500,229.00 in capital expenditures, free cash flow totaled -8.64M - equivalent to -15.65 per share.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -636.18: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -247.53, meaning Psyence Biomedical Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Psyence Biomedical Ltd.'s most recent stock split took place on February 2, 2026 with a 25:4 split ratio.

As of March 31, 2026, Psyence Biomedical Ltd. has an Altman Z-Score of -0.16, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.